Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 5
Submit an article Journal homepage
2,425
Views
4
CrossRef citations to date
0
Altmetric
Articles

Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?

Luca MastorinoDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7386-3219
ORCID Icon,
Paolo DapavoDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
,
Gianluca AvalloneDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
,
Martina MerliDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
,
Caterina CaritiDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
,
Marco RubattoDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
,
Valentina PalaDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
,
Pietro QuaglinoDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
&
Simone RiberoDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalyORCID Iconhttps://orcid.org/0000-0002-0098-1406
ORCID Icon show all
Pages 2495-2502 | Received 31 Jul 2021, Accepted 12 Aug 2021, Published online: 30 Aug 2021

References

  • Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
  • Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris–part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317.
  • Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;56(4):421–429.
  • Bellinato F, Gisondi P, Maurelli M, et al. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. Dermatol Ther. 2021;34(2):e14889.
  • Chyuan IT, Lai JH. New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol. 2020;175:113928.
  • Zhao J, Chen X, Herjan T, et al. The role of interleukin-17 in tumor development and progression. J Exp Med. 2020;217(1):e20190297.
  • Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–371.
  • Kamiya K, Yamauchi H, Ohtsuki M. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer. Eur J Dermatol. 2020;30(5):609–611.
  • Jin JQ, Ahlstrom JM, Sweeney NW, et al. Clinical characteristics of 18 patients with psoriasis and multiple myeloma identified through digital health crowdsourcing. Dermatol Ther. 2020;10(4):815–827.
  • Gambardella A. Secukinumab in the treatment of plaque psoriasis in patients with malignancy. Case Rep Dermatol. 2019;11(Suppl 1):11–16.
  • Ghazanfar MN, Karlsmark T, Danielsen PL, et al. Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis. Clin Case Rep. 2019;7(7):1350–1351.
  • Odorici G, Lasagni C, Bigi L, et al. A real-life experience of psoriatic patients with history of cancer treated with biological drugs. J Eur Acad Dermatol Venereol. 2019;33(12):e453–e455.
  • Lasagni C, Bigi L, Conti A, et al. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. J Dermatolog Treat. 2018;29(Suppl 2):5–8.
  • Wang DM, Fernandez AP, Calabrese CM, et al. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Clin Exp Dermatol. 2019;44(1):113–115.
  • Gkalpakiotis S, Arenberger P, Fridman M, et al. Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma. Dermatol Ther. 2017;30(6).
  • Patel S, Patel T, Kerdel FA. The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature. Int J Dermatol. 2016;55(5):487–493.
  • van Lümig PP, Driessen RJ, Berends MA, et al. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol. 2012;26(3):283–291.
  • Balato A, Lembo S, Cirillo T, Megna M, et al. Anti-Tumor necrosis factor-α therapy in the management of psoriasis and B-chronic lymphocytic leukemia. Case Rep Dermatol. 2011;3(1):60–63.
  • Yan J, Smyth MJ, Teng MWL. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb Perspect Biol. 2018;10(7)a028530.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.